1. Home
  2. ELOG vs INAB Comparison

ELOG vs INAB Comparison

Compare ELOG & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELOG

Eastern International Ltd. Ordinary Shares

HOLD

Current Price

$0.82

Market Cap

12.4M

Sector

Industrials

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.64

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELOG
INAB
Founded
2006
2016
Country
China
United States
Employees
N/A
17
Industry
Integrated Freight & Logistics
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
15.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ELOG
INAB
Price
$0.82
$1.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
7.9K
61.1K
Earning Date
07-17-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.12
52 Week High
$3.07
$4.20

Technical Indicators

Market Signals
Indicator
ELOG
INAB
Relative Strength Index (RSI) 34.69 56.43
Support Level N/A $1.52
Resistance Level $1.19 $2.14
Average True Range (ATR) 0.04 0.09
MACD -0.01 0.02
Stochastic Oscillator 4.57 75.86

Price Performance

Historical Comparison
ELOG
INAB

About ELOG Eastern International Ltd. Ordinary Shares

Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: